CA2520863A1 - 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 - Google Patents

4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 Download PDF

Info

Publication number
CA2520863A1
CA2520863A1 CA002520863A CA2520863A CA2520863A1 CA 2520863 A1 CA2520863 A1 CA 2520863A1 CA 002520863 A CA002520863 A CA 002520863A CA 2520863 A CA2520863 A CA 2520863A CA 2520863 A1 CA2520863 A1 CA 2520863A1
Authority
CA
Canada
Prior art keywords
6alkyl
aryl
substituents
2alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002520863A
Other languages
English (en)
French (fr)
Inventor
Nicholas D. P. Cosford
Dehua Huang
Nicholas D. Smith
Essa Hsinyi Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2520863A1 publication Critical patent/CA2520863A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002520863A 2003-04-03 2004-03-30 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 Abandoned CA2520863A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46002903P 2003-04-03 2003-04-03
US60/460,029 2003-04-03
PCT/US2004/009658 WO2004087653A2 (en) 2003-04-03 2004-03-30 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5

Publications (1)

Publication Number Publication Date
CA2520863A1 true CA2520863A1 (en) 2004-10-14

Family

ID=33131911

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002520863A Abandoned CA2520863A1 (en) 2003-04-03 2004-03-30 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5

Country Status (7)

Country Link
US (1) US20060217420A1 (enExample)
EP (1) EP1613615A2 (enExample)
JP (1) JP2006522128A (enExample)
CN (1) CN100422175C (enExample)
AU (1) AU2004225887A1 (enExample)
CA (1) CA2520863A1 (enExample)
WO (1) WO2004087653A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4286146B2 (ja) * 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
EP1482931B1 (en) 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
EP1485093B1 (en) * 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
EP1613614A2 (en) * 2003-04-03 2006-01-11 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CN1845915A (zh) * 2003-09-02 2006-10-11 默克公司 作为亲代谢谷氨酸受体－5的调节剂的联吡啶胺和醚类化合物
EP1715867A4 (en) * 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
WO2006123255A2 (en) * 2005-05-18 2006-11-23 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7858649B2 (en) * 2005-10-14 2010-12-28 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
WO2007113202A1 (en) 2006-03-31 2007-10-11 Glaxo Group Limited Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists
US7943622B2 (en) 2006-06-06 2011-05-17 Cornerstone Therapeutics, Inc. Piperazines, pharmaceutical compositions and methods of use thereof
WO2009097414A1 (en) * 2008-01-29 2009-08-06 Vanda Pharmaceuticals, Inc. Use of imidazolylalkyl-pyridines for the treatment of addictive disorders
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
KR20150064743A (ko) 2012-10-05 2015-06-11 트랜스테크 파르마 엘엘씨 경도 및 중등도 알츠하이머 병의 치료
US9969726B2 (en) * 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物
WO2021138540A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US660753A (en) * 1899-11-27 1900-10-30 Ferdinand-Christoph Von Heydebrand Und Der Lasa Artificial fuel.
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2462289C (en) * 2001-10-04 2010-02-23 Nicholas D. Cosford Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
AU2002365892A1 (en) * 2001-11-30 2003-06-17 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
EP1458708B1 (en) * 2001-12-18 2007-09-26 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
JP4286146B2 (ja) * 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
JP4357965B2 (ja) * 2001-12-21 2009-11-04 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピロールモジュレーター
EP1485093B1 (en) * 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
EP1613614A2 (en) * 2003-04-03 2006-01-11 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CN100537564C (zh) * 2003-04-04 2009-09-09 麦克公司 代谢型谷氨酸受体-5的二芳基取代三唑调节剂
EP1613265A4 (en) * 2003-04-04 2007-02-14 Merck & Co Inc DI-ARYL-SUBSTITUTED PYRROL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
CN1845915A (zh) * 2003-09-02 2006-10-11 默克公司 作为亲代谢谷氨酸受体－5的调节剂的联吡啶胺和醚类化合物
US20060189661A1 (en) * 2003-11-03 2006-08-24 Wagenen Bradford V Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1715867A4 (en) * 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5

Also Published As

Publication number Publication date
US20060217420A1 (en) 2006-09-28
WO2004087653A3 (en) 2005-03-24
CN100422175C (zh) 2008-10-01
WO2004087653A2 (en) 2004-10-14
CN1768055A (zh) 2006-05-03
JP2006522128A (ja) 2006-09-28
EP1613615A2 (en) 2006-01-11
AU2004225887A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
AU2002360621B2 (en) heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
CA2470519C (en) Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
EP1485093B1 (en) Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
CA2520870A1 (en) Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CA2469821C (en) Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
AU2004227854B2 (en) Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
CN100537564C (zh) 代谢型谷氨酸受体-5的二芳基取代三唑调节剂
US7105533B2 (en) Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
EP1613615A2 (en) 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
JP5860459B2 (ja) ｓＧＣ刺激薬

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued